These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 28631222

  • 21. Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension.
    White WB, Hauser RA, Rowse GJ, Ziemann A, Hewitt LA.
    Am J Cardiol; 2017 Apr 01; 119(7):1111-1115. PubMed ID: 28159196
    [Abstract] [Full Text] [Related]

  • 22. Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data.
    François C, Hauser RA, Aballéa S, Dorey J, Kharitonova E, Hewitt LA.
    J Med Econ; 2016 Apr 01; 19(5):515-25. PubMed ID: 26710315
    [Abstract] [Full Text] [Related]

  • 23. Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
    Isaacson S, Vernino S, Ziemann A, Rowse GJ, Kalu U, White WB.
    J Am Soc Hypertens; 2016 Oct 01; 10(10):755-762. PubMed ID: 27614923
    [Abstract] [Full Text] [Related]

  • 24. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).
    Hauser RA, Hewitt LA, Isaacson S.
    J Parkinsons Dis; 2014 Oct 01; 4(1):57-65. PubMed ID: 24326693
    [Abstract] [Full Text] [Related]

  • 25. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension.
    Palma JA, Norcliffe-Kaufmann L, Martinez J, Kaufmann H.
    Neurology; 2018 Oct 16; 91(16):e1539-e1544. PubMed ID: 30232253
    [Abstract] [Full Text] [Related]

  • 26. Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?
    Kaufmann H.
    Clin Auton Res; 2017 Jul 16; 27(Suppl 1):1-3. PubMed ID: 28623419
    [No Abstract] [Full Text] [Related]

  • 27. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.
    Isaacson SH, Skettini J.
    Vasc Health Risk Manag; 2014 Jul 16; 10():169-76. PubMed ID: 24729712
    [Abstract] [Full Text] [Related]

  • 28. Managing neurogenic orthostatic hypotension with droxidopa in a patient with Parkinson disease, atrial fibrillation, and hypertension.
    Mehdirad A, Karabin B, Gupta F.
    Clin Auton Res; 2017 Jul 16; 27(Suppl 1):25-27. PubMed ID: 28634637
    [No Abstract] [Full Text] [Related]

  • 29. Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.
    Keating GM.
    Drugs; 2015 Feb 16; 75(2):197-206. PubMed ID: 25559422
    [Abstract] [Full Text] [Related]

  • 30. Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303).
    Isaacson S, Shill HA, Vernino S, Ziemann A, Rowse GJ.
    J Parkinsons Dis; 2016 Oct 19; 6(4):751-759. PubMed ID: 27636856
    [Abstract] [Full Text] [Related]

  • 31. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
    Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, Mauney J, Feirtag M, Mathias CJ, NOH301 Investigators.
    Neurology; 2014 Jul 22; 83(4):328-35. PubMed ID: 24944260
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Droxidopa reduces postural sway in Parkinson disease patients with orthostatic hypotension.
    Marsili L, Duque KR, Sturchio A, Sobrero G, Premoli I, Dwivedi AK, Espay AJ, Merola A.
    Parkinsonism Relat Disord; 2022 Jun 22; 99():62-64. PubMed ID: 35605513
    [Abstract] [Full Text] [Related]

  • 35. Refractory orthostatic hypotension in a patient with a spinal cord injury: Treatment with droxidopa.
    Canosa-Hermida E, Mondelo-García C, Ferreiro-Velasco ME, Salvador-de la Barrera S, Montoto-Marqués A, Rodríguez-Sotillo A, Vizoso-Hermida JR.
    J Spinal Cord Med; 2018 Jan 22; 41(1):115-118. PubMed ID: 28114866
    [Abstract] [Full Text] [Related]

  • 36. The Treatment of Primary Orthostatic Hypotension.
    Hale GM, Valdes J, Brenner M.
    Ann Pharmacother; 2017 May 22; 51(5):417-428. PubMed ID: 28092986
    [Abstract] [Full Text] [Related]

  • 37. Diagnosing and treating neurogenic orthostatic hypotension in primary care.
    Kuritzky L, Espay AJ, Gelblum J, Payne R, Dietrich E.
    Postgrad Med; 2015 May 22; 127(7):702-15. PubMed ID: 26012731
    [Abstract] [Full Text] [Related]

  • 38. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension.
    Biaggioni I, Arthur Hewitt L, Rowse GJ, Kaufmann H.
    BMC Neurol; 2017 May 12; 17(1):90. PubMed ID: 28494751
    [Abstract] [Full Text] [Related]

  • 39. Droxidopa approved for neurogenic orthostatic hypotension.
    Traynor K.
    Am J Health Syst Pharm; 2014 Apr 01; 71(7):520. PubMed ID: 24644107
    [No Abstract] [Full Text] [Related]

  • 40. Chemical pharmacotherapy for the treatment of orthostatic hypotension.
    Cheshire WP.
    Expert Opin Pharmacother; 2019 Feb 01; 20(2):187-199. PubMed ID: 30376728
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.